Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease
characterized by airflow limitation that is not fully reversible. Bronchodilator therapy is the …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Fixed dose combination (FDC) dual bronchodilators that co‐administer a long acting β2‐
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …

In this review, we summarize the rationale for combining long-acting bronchodilators in the
management of chronic obstructive pulmonary disease (COPD), and the evidence for the …

Introduction Inhaled β-agonists have been foundational medications for maintenance COPD
management for decades. Through activation of cyclic adenosine monophosphate …

Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory
symptoms, such as breathlessness and chronic productive cough, limited exercise …

Maintenance bronchodilator therapy with long-acting β-agonists (LABAs) and long-acting
muscarinic antagonists (LAMAs) is the cornerstone treatment for patients with stable chronic …

Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Current guidelines recommend treatment with one or more bronchodilators for chronic
obstructive pulmonary disease (COPD) patients. Combination therapy with long-acting …